#USA #Seattle #Pillar Biosciences #NGS Technology #AMP Annual Meeting

Pillar Biosciences Showcases NGS Innovations at AMP Annual Meeting in Seattle

Pillar Biosciences, a leading provider of next-generation sequencing (NGS) solutions, is set to present a series of groundbreaking scientific posters at the 2026 Association for Molecular Pathology (AMP) Annual Meeting taking place in Seattle, WA from November 10-14. With a total of ten posters highlighting their innovative NGS technology, the event promises to be a significant showcase for advancements in precision oncology.

Presentations Highlighting NGS Technology

Among the exciting presentations at the AMP Annual Meeting, Pillar will hold a platform presentation and three corporate workshops where prominent laboratory leaders will share their insights on rapid NGS applications. The workshops will feature discussions from esteemed institutions such as Duke University Medical Center, the University of Pennsylvania Health System, and the European Institute of Oncology, focusing on real-world applications of Pillar's NGS products.

Dan Harma, Chief Commercial Officer of Pillar Biosciences, emphasized the growing need for rapid NGS solutions across various domains—including solid tumors, hematologic malignancies, and liquid biopsies. He stated, “Laboratories' need for rapid NGS has expanded steadily, which shows that our technology is becoming a vital tool in monitoring measurable residual disease and improving patient outcomes in precision oncology.”

Key Sessions at the Meeting

Corporate Workshops

• - Evaluation and Analytical Validation of a Rapid NGS Panel: Led by Sarah Rapisardo, Ph.D., and Barbara Anderson, Ph.D. from Duke University Medical Center, this session will explore the effectiveness of rapid NGS in evaluating lymphoid malignancies.
• - Bringing Liquid Biopsy Closer to Patients: Konstantinos Venetis, Ph.D. from the European Institute of Oncology will discuss advancements in local NGS testing for biomarker assessment in advanced breast cancer.
• - Scaling Clinical Implementation of oncoReveal® Myeloid NGS: Hosted by Sarah Herlihy, Ph.D., and AmandaSue Landi, M.S. from the University of Pennsylvania Health System, the session will cover the oncoReveal Myeloid NGS on the MiSeq i100 instrument.

Platform Presentations

Additionally, attendees can look forward to the platform presentation on November 14, where Advocate Clinical Laboratories will present their findings on the efficient NGS detection of actionable AML variants, including FLT3-ITDs.

Significant Scientific Poster Presentations

Pillar Biosciences will also exhibit notable scientific posters, including:

• - Research on how to infer copy number variations from a targeted amplicon liquid biopsy panel without the need for matched baseline controls.
• - Using high-efficiency low-input amplicon chemistry to enhance molecular testing in prostate tissue samples.
• - An integrated DNA/RNA amplicon panel designed for rapid genomic profiling of actionable biomarkers in solid tumors.
• - Advanced techniques for assessing ctDNA ESR1 and multi-gene testing in metastatic breast cancer.

These efforts underscore Pillar's commitment to making precise NGS a front-line tool in modern oncology practices.

Conclusion

Pillar Biosciences is at the forefront of NGS advancements, and their participation in the AMP Annual Meeting highlights their pivotal role in enhancing cancer diagnostics. Attendees can expect invaluable insights and emerging technologies that could redefine how next-generation sequencing is utilized in the diagnosis and monitoring of various malignancies. For more information about Pillar Biosciences and their innovative solutions, visit their website at pillarbiosci.com and follow them on LinkedIn.

As the landscape of cancer genomics continues to evolve, events like this reaffirm the importance of collaboration and innovation in the quest for effective cancer treatments.